Rilonacept , takođe poznat kao IL-1 Trap i Arcalyst , je inhibotor interleukina 1 .[1] [2] [3] [4] [5] [6]
Reference [ уреди ]
^ "The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study " Oct 2009^ Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, Weinstein SP: Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012 Oct;34(10):2091-103. doi: 10.1016/j.clinthera.2012.09.009. Epub 2012 Sep 29. PMID 23031624
^ Tran TH, Pham JT, Shafeeq H, Manigault KR, Arya V: Role of Interleukin-1 Inhibitors in the Management of Gout. Pharmacotherapy. 2013 Apr 3. doi: 10.1002/phar.1265. PMID 23553601
^ Hawkins PN, Lachmann HJ, McDermott MF: Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med. 2003 Jun 19;348(25):2583-4. PMID 12815153
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs” . Nucleic Acids Res . 39 (Database issue): D1035—41. PMC 3013709 PMID 21059682 . doi :10.1093/nar/gkq1126 . уреди ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets” . Nucleic acids research . 36 (Database issue): D901—6. PMC 2238889 PMID 18048412 . doi :10.1093/nar/gkm958 . уреди
Literatura [ уреди ] Spoljašnje veze [ уреди ] Intracelularni
Intracelularni
Ekstracelularni
Antitela
Monoklonalna
Serum cilj Celularni ciljevi CD3 (
Muromonab-CD3 ,
Oteliksizumab ,
Teplizumab ,
Visilizumab ) •
CD4 (
Klenoliksimab ,
Keliksimab ,
Zanolimumab ) •
CD11a (
Efalizumab ) •
CD18 (
Erlizumab ) •
CD20 (
Afutuzumab ,
Ocrelizumab ,
Pascolizumab ) •
CD23 (
Lumiliksimab ) •
CD40 (
Teneliksimab ,
Toralizumab ) •
CD62L/L-selektin (
Aselizumab ) •
CD80 (
Galiksimab ) •
CD147/Basigin (
Gavilimomab ) •
CD154 (
Ruplizumab )
BLyS Belimumab ) • CTLA-4 Ipilimumab , Tremelimumab ) • CAT Bertilimumab , Lerdelimumab , Metelimumab ) • Integrin Natalizumab ) • Interleukin-6 receptor Tocilizumab ) • LFA-1 Odulimomab )
IL-2 receptor/CD25 Basiliksimab , Daklizumab , Inolimomab )
T-limfocit (
Zolimomab aritoks )
Nesortirani Atorolimumab ,
Cedelizumab ,
Dorliksizumab ,
Fontolizumab ,
Gantenerumab ,
Gomiliksimab ,
Maslimomab ,
Morolimumab ,
Pekselizumab ,
Reslizumab ,
Rovelizumab ,
Siplizumab ,
Talizumab ,
Telimomab aritoks ,
Vapaliksimab ,
Vepalimomab
Poliklonalna
-cept (Fuzija )
Molimo Vas, obratite pažnju na važno upozorenje oblasti medicine (zdravlja) .
. PMID 21059682. doi:10.1093/nar/gkq1126.
